Announcements Trials
Browse Landscape

Status

Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Observational 4Interventional 3

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 1214Urinary Bladder Neoplasms 386Carcinoma, Renal Cell 329Kidney Neoplasms 205Neoplasms 157Breast Neoplasms 146Lung Neoplasms 101Carcinoma, Transitional Cell 99Colorectal Neoplasms 77Testicular Neoplasms 74Ovarian Neoplasms 62Melanoma 60Pancreatic Neoplasms 57Colonic Neoplasms 50Carcinoma, Non-Small-Cell Lung 50Head and Neck Neoplasms 47Stomach Neoplasms 45Non-Muscle Invasive Bladder Neoplasms 45Disease 45Neoplasm Metastasis 41Liver Neoplasms 40Uterine Cervical Neoplasms 39Esophageal Neoplasms 37Wilms Tumor 36Prostatic Hyperplasia 36Adenocarcinoma 33Multiple Myeloma 32Urologic Neoplasms 30Sarcoma 30Recurrence 30

Interventions

enzalutamide 1darolutamide 1apalutamide 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × Metastatic Hormone-sensitive Prostate Cancer × Genitourinary × Clear all
NCT05901649 2026-05-08

ArtemisPRO

Janssen-Cilag Ltd.

Active not recruiting
504 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06874114 2026-04-13

RE-ENGAGE

Bayer

Active not recruiting
700 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT07031258 2025-06-22

Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer

Nanfang Hospital, Southern Medical University

Not yet recruiting
50 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

NCT06498921 2024-10-24

BELBEQA

Bayer

Completed
106 enrolled
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡